BRAF-话题@MedSci

#BRAF#

112篇内容 | 3453人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1354994, encodeId=3a6a13549943c, content=<a href='/topic/show?id=6de63659ed' target=_blank style='color:#2F92EE;'>#BRAF#</a>, objectTitle=JCO：男性甲状腺乳头状癌预后是否更差？BRAF V600E突变说了算, objectType=article, longId=146521, objectId=b8dc14652188, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b8dc14652188, replyNumber=0, likeNumber=68, createdTime=2018-08-14, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b8dc14652188, moduleTitle=JCO：男性甲状腺乳头状癌预后是否更差？BRAF V600E突变说了算, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b8dc14652188)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1354993, encodeId=1b141354993ab, content=<a href='/topic/show?id=6de63659ed' target=_blank style='color:#2F92EE;'>#BRAF#</a>, objectTitle=Braftovi/Mektovi联合在美国获批用于BRAF突变转移性黑素瘤, objectType=article, longId=141927, objectId=83be14192e7c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=83be14192e7c, replyNumber=0, likeNumber=69, createdTime=2018-06-30, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=83be14192e7c, moduleTitle=Braftovi/Mektovi联合在美国获批用于BRAF突变转移性黑素瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=83be14192e7c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1354992, encodeId=62011354992ba, content=<a href='/topic/show?id=6de63659ed' target=_blank style='color:#2F92EE;'>#BRAF#</a>, objectTitle=Clin Oral Investig：免疫组化分析成釉细胞瘤中的BRAF V600E突变, objectType=article, longId=139868, objectId=d6e31398680b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d6e31398680b, replyNumber=0, likeNumber=103, createdTime=2018-06-05, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d6e31398680b, moduleTitle=Clin Oral Investig：免疫组化分析成釉细胞瘤中的BRAF V600E突变, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d6e31398680b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1354991, encodeId=3d02135499132, content=<a href='/topic/show?id=6de63659ed' target=_blank style='color:#2F92EE;'>#BRAF#</a>, objectTitle=JAMA SURGERY：BRAF突变与结直肠癌肝转移患者肿瘤切除后生存和复发的关系, objectType=article, longId=139631, objectId=62421396314a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=62421396314a, replyNumber=0, likeNumber=64, createdTime=2018-06-02, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=62421396314a, moduleTitle=JAMA SURGERY：BRAF突变与结直肠癌肝转移患者肿瘤切除后生存和复发的关系, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=62421396314a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1354990, encodeId=8498135499093, content=<a href='/topic/show?id=6de63659ed' target=_blank style='color:#2F92EE;'>#BRAF#</a>, objectTitle=CLIN CHEM：黑色素瘤患者血浆中循环肿瘤DNA的液体分析用于伴随诊断和BRAF抑制剂治疗的监测, objectType=article, longId=138830, objectId=1e7b1388303f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1e7b1388303f, replyNumber=0, likeNumber=0, createdTime=2018-05-24, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1e7b1388303f, moduleTitle=CLIN CHEM：黑色素瘤患者血浆中循环肿瘤DNA的液体分析用于伴随诊断和BRAF抑制剂治疗的监测, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1e7b1388303f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1354989, encodeId=d44c135498903, content=<a href='/topic/show?id=6de63659ed' target=_blank style='color:#2F92EE;'>#BRAF#</a>, objectTitle=诺华BRAF抑制剂与MEK抑制剂获FDA批准联合靶向治疗黑色素瘤, objectType=article, longId=137007, objectId=d64a13e007c3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d64a13e007c3, replyNumber=0, likeNumber=69, createdTime=2018-05-04, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d64a13e007c3, moduleTitle=诺华BRAF抑制剂与MEK抑制剂获FDA批准联合靶向治疗黑色素瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d64a13e007c3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1354988, encodeId=83e01354988de, content=<a href='/topic/show?id=6de63659ed' target=_blank style='color:#2F92EE;'>#BRAF#</a>, objectTitle=联合靶向BRAF和HSP90的药物显示了黑素瘤治疗潜能, objectType=article, longId=136724, objectId=5b79136e249e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5b79136e249e, replyNumber=0, likeNumber=70, createdTime=2018-04-29, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5b79136e249e, moduleTitle=联合靶向BRAF和HSP90的药物显示了黑素瘤治疗潜能, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5b79136e249e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1354987, encodeId=19bf135498e7c, content=<a href='/topic/show?id=6de63659ed' target=_blank style='color:#2F92EE;'>#BRAF#</a>, objectTitle=JAMA ONCOL：西妥昔单抗+改良FOLFOXIR后持续西妥昔单抗或贝伐单抗治疗RAS和BRAF野生型转移性结直肠癌I, objectType=article, longId=136508, objectId=62cf1365087c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=62cf1365087c, replyNumber=0, likeNumber=65, createdTime=2018-04-27, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=62cf1365087c, moduleTitle=JAMA ONCOL：西妥昔单抗+改良FOLFOXIR后持续西妥昔单抗或贝伐单抗治疗RAS和BRAF野生型转移性结直肠癌I, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=62cf1365087c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1354986, encodeId=8709135498658, content=<a href='/topic/show?id=6de63659ed' target=_blank style='color:#2F92EE;'>#BRAF#</a>, objectTitle=Lancet Oncol：新的BRAF/MEK联合抑制方案用于BRAF突变型黑色素瘤, objectType=article, longId=134563, objectId=3e681345639b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3e681345639b, replyNumber=0, likeNumber=0, createdTime=2018-04-10, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3e681345639b, moduleTitle=Lancet Oncol：新的BRAF/MEK联合抑制方案用于BRAF突变型黑色素瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3e681345639b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1354985, encodeId=ca4b1354985b4, content=<a href='/topic/show?id=6de63659ed' target=_blank style='color:#2F92EE;'>#BRAF#</a>, objectTitle=CLIN CANCER RES：PI3K和BRAF联合抑制治疗晚期BRAF V600突变实体肿瘤, objectType=article, longId=125958, objectId=870a12595850, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=870a12595850, replyNumber=0, likeNumber=71, createdTime=2018-01-10, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=870a12595850, moduleTitle=CLIN CANCER RES：PI3K和BRAF联合抑制治疗晚期BRAF V600突变实体肿瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=870a12595850)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1354984, encodeId=7c481354984d7, content=<a href='/topic/show?id=6de63659ed' target=_blank style='color:#2F92EE;'>#BRAF#</a>, objectTitle=EUR J Cancer：转移性结直肠癌治疗中，BRAF和RAS突变对一线疗法（FOLFIRI加西妥昔单抗，FOLFIRI加贝伐单抗）的影响, objectType=article, longId=125177, objectId=1e501251e7c5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1e501251e7c5, replyNumber=0, likeNumber=64, createdTime=2018-01-01, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1e501251e7c5, moduleTitle=EUR J Cancer：转移性结直肠癌治疗中，BRAF和RAS突变对一线疗法（FOLFIRI加西妥昔单抗，FOLFIRI加贝伐单抗）的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1e501251e7c5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1354983, encodeId=43e31354983ad, content=<a href='/topic/show?id=6de63659ed' target=_blank style='color:#2F92EE;'>#BRAF#</a>, objectTitle=EUR J Cancer：BRAF / MEK抑制剂的使用会产生脱髓鞘性多发性神经根神经病变, objectType=article, longId=125006, objectId=5ee4125006c9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5ee4125006c9, replyNumber=0, likeNumber=61, createdTime=2017-12-30, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5ee4125006c9, moduleTitle=EUR J Cancer：BRAF / MEK抑制剂的使用会产生脱髓鞘性多发性神经根神经病变, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5ee4125006c9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1354982, encodeId=27751354982ea, content=<a href='/topic/show?id=6de63659ed' target=_blank style='color:#2F92EE;'>#BRAF#</a>, objectTitle=Lancet Gastroen Hepatol：BRAF， PIK3CA， KRAS以及 NRAS野生型晚期或转移性结直肠癌患者多信号通路联合治疗研究, objectType=article, longId=123846, objectId=166d123846a2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=166d123846a2, replyNumber=0, likeNumber=50, createdTime=2017-12-20, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=166d123846a2, moduleTitle=Lancet Gastroen Hepatol：BRAF， PIK3CA， KRAS以及 NRAS野生型晚期或转移性结直肠癌患者多信号通路联合治疗研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=166d123846a2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1354981, encodeId=468713549811f, content=<a href='/topic/show?id=6de63659ed' target=_blank style='color:#2F92EE;'>#BRAF#</a>, objectTitle=JCO：甲状腺乳头状癌患者年龄相关死亡风险与BRAFV600E有关, objectType=article, longId=123572, objectId=a8b11235e299, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a8b11235e299, replyNumber=0, likeNumber=23, createdTime=2017-12-17, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a8b11235e299, moduleTitle=JCO：甲状腺乳头状癌患者年龄相关死亡风险与BRAFV600E有关, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a8b11235e299)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1354980, encodeId=237013549807a, content=<a href='/topic/show?id=6de63659ed' target=_blank style='color:#2F92EE;'>#BRAF#</a>, objectTitle=全球用于治疗BRAFV600突变阳性的无法手术切除或转移性黑色素瘤的靶向新药佐博伏® 中国上市 CFDA审评概述, objectType=article, longId=122007, objectId=8d8a12200e1b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8d8a12200e1b, replyNumber=0, likeNumber=25, createdTime=2017-12-03, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8d8a12200e1b, moduleTitle=全球用于治疗BRAFV600突变阳性的无法手术切除或转移性黑色素瘤的靶向新药佐博伏® 中国上市 CFDA审评概述, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8d8a12200e1b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1354979, encodeId=88a913549e989, content=<a href='/topic/show?id=6de63659ed' target=_blank style='color:#2F92EE;'>#BRAF#</a>, objectTitle=Oral Oncol：牙源性角化囊肿与致癌基因BRAF V600E突变频率的关系, objectType=article, longId=121600, objectId=96cc121600cb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=96cc121600cb, replyNumber=0, likeNumber=96, createdTime=2017-11-29, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=96cc121600cb, moduleTitle=Oral Oncol：牙源性角化囊肿与致癌基因BRAF V600E突变频率的关系, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=96cc121600cb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1354978, encodeId=436413549e8fe, content=<a href='/topic/show?id=6de63659ed' target=_blank style='color:#2F92EE;'>#BRAF#</a>, objectTitle=JAMA Oncology：RAS和BRAF突变Ⅲ期结肠癌患者肿瘤位置的预后价值, objectType=article, longId=121370, objectId=943f1213e0f9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=943f1213e0f9, replyNumber=0, likeNumber=81, createdTime=2017-11-27, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=943f1213e0f9, moduleTitle=JAMA Oncology：RAS和BRAF突变Ⅲ期结肠癌患者肿瘤位置的预后价值, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=943f1213e0f9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1354977, encodeId=fc2713549e741, content=<a href='/topic/show?id=6de63659ed' target=_blank style='color:#2F92EE;'>#BRAF#</a>, objectTitle=NEJM：Dabrafenib联合Trametinib可显著降低III期BRAF V600突变黑色素瘤患者的术后复发风险, objectType=article, longId=119397, objectId=b09511939ebc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b09511939ebc, replyNumber=0, likeNumber=62, createdTime=2017-11-11, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b09511939ebc, moduleTitle=NEJM：Dabrafenib联合Trametinib可显著降低III期BRAF V600突变黑色素瘤患者的术后复发风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b09511939ebc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1354976, encodeId=cd7113549e641, content=<a href='/topic/show?id=6de63659ed' target=_blank style='color:#2F92EE;'>#BRAF#</a>, objectTitle=JCO：Dabrafenib和Trametinib治疗局部晚期或转移性BRAFV600突变甲状腺未分化癌, objectType=article, longId=118188, objectId=f3d911818880, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f3d911818880, replyNumber=0, likeNumber=26, createdTime=2017-11-01, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f3d911818880, moduleTitle=JCO：Dabrafenib和Trametinib治疗局部晚期或转移性BRAFV600突变甲状腺未分化癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f3d911818880)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1354975, encodeId=36ae13549e503, content=<a href='/topic/show?id=6de63659ed' target=_blank style='color:#2F92EE;'>#BRAF#</a>, objectTitle=Lancet Oncol：为Braf突变的晚期肺癌患者提供一条新的诊疗思路, objectType=article, longId=117266, objectId=39cc11e26686, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=39cc11e26686, replyNumber=0, likeNumber=75, createdTime=2017-10-25, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=39cc11e26686, moduleTitle=Lancet Oncol：为Braf突变的晚期肺癌患者提供一条新的诊疗思路, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=39cc11e26686)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

BRAF

2020-05-29

zhaojie88 (审核中...)

前往app查看评论内容

#BRAF#

JCO：男性甲状腺乳头状癌预后是否更差？BRAF V600E突变说了算

2018-08-14

zhaojie88 (审核中...)

前往app查看评论内容

#BRAF#

Braftovi/Mektovi联合在美国获批用于BRAF突变转移性黑素瘤

2018-06-30

zhaojie88 (审核中...)

前往app查看评论内容

#BRAF#

Clin Oral Investig：免疫组化分析成釉细胞瘤中的BRAF V600E突变

2018-06-05

zhaojie88 (审核中...)

前往app查看评论内容

#BRAF#

JAMA SURGERY：BRAF突变与结直肠癌肝转移患者肿瘤切除后生存和复发的关系

2018-06-02

zhaojie88 (审核中...)

前往app查看评论内容

#BRAF#

CLIN CHEM：黑色素瘤患者血浆中循环肿瘤DNA的液体分析用于伴随诊断和BRAF抑制剂治疗的监测

2018-05-24

zhaojie88 (审核中...)

前往app查看评论内容

#BRAF#

诺华BRAF抑制剂与MEK抑制剂获FDA批准联合靶向治疗黑色素瘤

2018-05-04

zhaojie88 (审核中...)

前往app查看评论内容

#BRAF#

联合靶向BRAF和HSP90的药物显示了黑素瘤治疗潜能

2018-04-29

zhaojie88 (审核中...)

前往app查看评论内容

#BRAF#

JAMA ONCOL：西妥昔单抗+改良FOLFOXIR后持续西妥昔单抗或贝伐单抗治疗RAS和BRAF野生型转移性结直肠癌I

2018-04-27

zhaojie88 (审核中...)

前往app查看评论内容

#BRAF#

Lancet Oncol：新的BRAF/MEK联合抑制方案用于BRAF突变型黑色素瘤

2018-04-10

zhaojie88 (审核中...)

前往app查看评论内容

#BRAF#

CLIN CANCER RES：PI3K和BRAF联合抑制治疗晚期BRAF V600突变实体肿瘤

2018-01-10

zhaojie88 (审核中...)

前往app查看评论内容

#BRAF#

EUR J Cancer：转移性结直肠癌治疗中，BRAF和RAS突变对一线疗法（FOLFIRI加西妥昔单抗，FOLFIRI加贝伐单抗）的影响

2018-01-01

zhaojie88 (审核中...)

前往app查看评论内容

#BRAF#

EUR J Cancer：BRAF / MEK抑制剂的使用会产生脱髓鞘性多发性神经根神经病变

2017-12-30

zhaojie88 (审核中...)

前往app查看评论内容

#BRAF#

Lancet Gastroen Hepatol：BRAF， PIK3CA， KRAS以及 NRAS野生型晚期或转移性结直肠癌患者多信号通路联合治疗研究

2017-12-20

zhaojie88 (审核中...)

前往app查看评论内容

#BRAF#

JCO：甲状腺乳头状癌患者年龄相关死亡风险与BRAFV600E有关

2017-12-17

zhaojie88 (审核中...)

前往app查看评论内容

#BRAF#

全球用于治疗BRAFV600突变阳性的无法手术切除或转移性黑色素瘤的靶向新药佐博伏® 中国上市 CFDA审评概述

2017-12-03

zhaojie88 (审核中...)

前往app查看评论内容

#BRAF#

Oral Oncol：牙源性角化囊肿与致癌基因BRAF V600E突变频率的关系

2017-11-29

zhaojie88 (审核中...)

前往app查看评论内容

#BRAF#

JAMA Oncology：RAS和BRAF突变Ⅲ期结肠癌患者肿瘤位置的预后价值

2017-11-27

zhaojie88 (审核中...)

前往app查看评论内容

#BRAF#

NEJM：Dabrafenib联合Trametinib可显著降低III期BRAF V600突变黑色素瘤患者的术后复发风险

2017-11-11

zhaojie88 (审核中...)

前往app查看评论内容

#BRAF#

JCO：Dabrafenib和Trametinib治疗局部晚期或转移性BRAFV600突变甲状腺未分化癌

2017-11-01

zhaojie88 (审核中...)

前往app查看评论内容

#BRAF#

Lancet Oncol：为Braf突变的晚期肺癌患者提供一条新的诊疗思路

2017-10-25

科室
- - 订阅+
  - 更多科室
工具
服务